Edition:
United Kingdom

Kala Pharmaceuticals Inc (KALA.OQ)

KALA.OQ on NASDAQ Stock Exchange Global Select Market

16.65USD
15 Dec 2017
Change (% chg)

$0.34 (+2.08%)
Prev Close
$16.31
Open
$16.30
Day's High
$17.32
Day's Low
$16.00
Volume
474,038
Avg. Vol
60,594
52-wk High
$26.74
52-wk Low
$13.54

Chart for

About

Kala Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of therapeutics through its nanoparticle-based Mucus Penetrating Particles, or MPP, technology. The Company’s initial focus is on the treatment of eye diseases. The Company’s product candidate includes KPI-121 1%, KPI-121... (more)

Overall

Beta: --
Market Cap(Mil.): $547.77
Shares Outstanding(Mil.): 24.23
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 88.66 16.44
EPS (TTM): -- -- --
ROI: -- 2.36 10.62
ROE: -- 2.96 14.20

BRIEF-Kala Pharmaceuticals reports Q3 loss per share $0.56

* Kala Pharmaceuticals reports third quarter 2017 financial results and provides business update

07 Nov 2017

BRIEF-Kala Pharmaceuticals submits new drug application for Inveltystm

* Kala pharmaceuticals submits new drug application to U.S. Food and Drug Administration for Inveltystm (KPI-121 1 pct) Source text for Eikon: Further company coverage:

25 Oct 2017

BRIEF-Wellington Management Group reports 11.84 pct passive stake in Kala Pharmaceuticals - SEC filing‍​

* Wellington Management Group LLP reports 11.84 percent passive stake in Kala Pharmaceuticals Inc as of July 31, 2017 - SEC filing‍​ Source text: (http://bit.ly/2wxa3C9) Further company coverage: (Bengaluru Newsroom: +91 806 749 1136)

10 Aug 2017

BRIEF-Hadley Harbor Master Investors (Cayman) L.P. reports 7.45 pct passive stake in Kala Pharmaceuticals Inc

* Hadley Harbor Master Investors (Cayman) L.P. reports 7.45 percent passive stake in Kala Pharmaceuticals Inc as on July 20, 2017 - Sec Filing‍​ Source text (http://bit.ly/2uNGNIC) Further company coverage:

31 Jul 2017

BRIEF-Kala Pharma announces pricing of initial public offering

* Kala Pharmaceuticals announces pricing of initial public offering

20 Jul 2017

BRIEF-Kala Pharma sees IPO of 6 mln shares priced between $14-$16/shr

* Kala Pharmaceuticals sees IPO of 6 million shares of co's common stock priced between $14.00 and $16.00 per share Source text: (http://bit.ly/2tFlt5R) Further company coverage:

10 Jul 2017

Earnings vs. Estimates